IRS4 (Insulin receptor substrate 4) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer and 4 more. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Biology
Acts as an interface between multiple growth factor receptors possessing tyrosine kinase activity, such as insulin receptor, IGF1R and FGFR1, and a complex network of intracellular signalling molecules containing SH2 domains. Involved in the IGF1R mitogenic signalling pathway. Promotes the AKT1 signalling pathway and BAD phosphorylation during insulin stimulation without activation of RPS6KB1 or the inhibition of apoptosis. Interaction with GRB2 enhances insulin-stimulated mitogen-activated protein kinase activity. May be involved in nonreceptor tyrosine kinase signalling in myoblasts. Plays a pivotal role in the proliferation/differentiation of hepatoblastoma cell through EPHB2 activation upon IGF1 stimulation. Location: Cell membrane (UniProt). Locus Xq22.3 (HGNC).
- Bladder & urothelial cancer: IntOGen driver in 1 cohort (BLCA)
- Pancreatic ductal adenocarcinoma: IntOGen driver in 1 cohort (PAAD)
- Colorectal cancer: Open Targets association 0.53 with colorectal cancer (MONDO_0005575)
- Lung cancer: Open Targets association 0.52 with lung cancer (MONDO_0008903)
- Skin cancer: Open Targets association 0.51 with skin cancer (MONDO_0002898)
- Melanoma: Open Targets association 0.53 with melanoma (MONDO_0005105)
External identifiers
Built from HGNC, Ensembl, UniProt and ChEMBL idsProducts by modality and phase
Browse products →No product in the corpus is aimed at this target yet.
Trials
Evidence ranking →No trial in the corpus names this target or one of its products.
Resistance routes
Unaddressed routes →The resistance atlas has no route that names this target.
Pathways
Pathway-to-drug matrix →No pathway diagram carries this target as a node.
Companion diagnostics
Assay registry →No companion diagnostic in the registry measures this target.
Preclinical models
All models →No model entry for this target yet; check the cancer entries on the models page.
Open questions
All open questions →No open questions recorded for this target yet. Suggest one.
Literature
Preprints →Query for this target: (TITLE:"IRS4" OR ABSTRACT:"IRS4" OR TITLE:"insulin receptor substrate 4" OR ABSTRACT:"insulin receptor substrate 4" OR TITLE:"Insulin receptor substrate 4" OR ABSTRACT:"Insulin receptor substrate 4" OR TITLE:"PY160" OR ABSTRACT:"PY160" OR TITLE:"IRS-4" OR ABSTRACT:"IRS-4") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about IRS4, not a curated reading list.
Export
The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/irs4.json. Licence CC BY-NC 4.0.